Injection-site reactions upon Kineret (anakinra) administration: Experiences and explanations

Rheumatology International

Volumn 32, Issue 2, 2012, Pages 295-299

  Kaiser, Christina ^a   Knight, Ann ^b   Nordström, Dan ^c   Pettersson, Tom ^c   Fransson, Jonas ^a   Florin Robertsson, Ebba ^a   Pilström, Björn ^a  

^a BIOVITRUM AB   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Anakinra; Injection site reactions; Kineret

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DRUG VEHICLE; INTERLEUKIN 1; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POLYSORBATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADVERSE OUTCOME; ANTIINFLAMMATORY ACTIVITY; COMBINATION CHEMOTHERAPY; DRUG FORMULATION; DRUG HALF LIFE; ECCHYMOSIS; ERYTHEMA; HUMAN; INFLAMMATION; INJECTION SITE REACTION; PAIN; PRIORITY JOURNAL; PRURITUS; REVIEW; RHEUMATOID ARTHRITIS; SWELLING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN;

EID: 84857057601     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-2096-3     Document Type: Review

References (29)

1. D Zanette, et al. 1998 Human IL-1 receptor antagonist from Escherichia coli: large-scale microbial growth and protein purification J Biotechnol 64 2-3 187 196 9821675 10.1016/S0168-1656(98)00111-4 1:CAS:528:DyaK1cXntVygsrw%3D (Pubitemid 29027803)
2. WP Arend C Gabay 2000 Physiologic role of interleukin-1 receptor antagonist Arthritis Res 2 4 245 248 11094434 10.1186/ar94 1:CAS:528: DC%2BD3cXmtVKjs7s%3D (Pubitemid 32223740)
3. Clarke JB Mechanisms of adverse drug reactions to biologics. Handb Exp Pharmacol (196):453-474
4. M Mertens JA Singh 2009 Anakinra for rheumatoid arthritis: a systematic review J Rheumatol 36 6 1118 1125 19447938 10.3899/jrheum.090074 1:CAS:528:DC%2BD1MXotlSjt74%3D
5. A Bendele, et al. 1995 Cutaneous mast cell degranulation in rats receiving injections of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) and/or its vehicle: possible clinical implications J Lab Clin Med 125 4 493 500 7706905 1:CAS:528:DyaK2MXlsVChsrg%3D
6. S Cohen, et al. 2002 Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum 46 3 614 624 11920396 10.1002/art.10141 1:CAS:528:DC%2BD38XisFOmt7w%3D (Pubitemid 34214243)
7. AA Raibekas, et al. 2005 Anion binding and controlled aggregation of human interleukin-1 receptor antagonist Biochemistry 44 29 9871 9879 16026159 10.1021/bi050388g 1:CAS:528:DC%2BD2MXls1ajsL0%3D (Pubitemid 41033453)
8. YC Wang RR Kowal 1980 Review of excipients and pH's for parenteral products used in the United States J Parenter Drug Assoc 34 6 452 462 6906368 1:CAS:528:DyaL3MXht1OitLk%3D (Pubitemid 11177107)
9. J Fransson A Espander-Jansson 1996 Local tolerance of subcutaneous injections J Pharm Pharmacol 48 10 1012 1015 8953501 10.1111/j.2042-7158.1996. tb05892.x 1:CAS:528:DyaK2sXhs1Gmtw%3D%3D (Pubitemid 26400289)
10. LA Frenken, et al. 1993 Identification of the component part in an epoetin alfa preparation that causes pain after subcutaneous injection Am J Kidney Dis 22 4 553 556 8213795 1:STN:280:DyaK2c%2FislShtQ%3D%3D (Pubitemid 23308965)
11. T Laursen B Hansen S Fisker 2006 Pain perception after subcutaneous injections of media containing different buffers Basic Clin Pharmacol Toxicol 98 2 218 221 16445598 10.1111/j.1742-7843.2006.pto-271.x 1:CAS:528: DC%2BD28XhvFOrur0%3D
12. Steele RH et al. (2005) Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin. Nephrology (Carlton) 10(3):317-320 (Pubitemid 40910382)
13. L Konttinen, et al. 2006 Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study Clin Rheumatol 25 6 882 884 16552464 10.1007/s10067-006- 00243-0 (Pubitemid 44473158)
14. AA den Broeder, et al. 2006 Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice Ann Rheum Dis 65 6 760 762 10.1136/ard.2004.033662 (Pubitemid 43799175)
15. G Karanikolas, et al. 2008 Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study Rheumatology (Oxford) 47 9 1384 1388 10.1093/rheumatology/ken223 1:CAS:528:DC%2BD1cXhtV2isbrJ
16. AT Vila, et al. 2005 Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients Br J Dermatol 153 2 417 423 16086759 10.1111/j.1365-2133.2005.06635.x 1:STN:280:DC%2BD2Mvit1WgsQ%3D%3D (Pubitemid 41228444)
17. Saunders C et al. Factors that influence adherence and strategies to maintain adherence to injected therapies for patients with multiple sclerosis. J Neurosci Nurs 42(5 Suppl):S10-S8
18. AE Moustou, et al. 2009 Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review J Am Acad Dermatol 61 3 486 504 19628303 10.1016/j.jaad.2008.10.060 1:CAS:528:DC%2BD1MXhtFOitrzF
19. H Winfield, et al. 2006 Eosinophilic cellulitislike reaction to subcutaneous etanercept injection Arch Dermatol 142 2 218 220 16490850 10.1001/archderm.142.2.218 (Pubitemid 43276535)
20. A Rivkin 2009 Certolizumab pegol for the management of Crohn's disease in adults Clin Ther 31 6 1158 1176 19695385 10.1016/j.clinthera.2009.06.015 1:CAS:528:DC%2BD1MXhtVCht7rE
21. P Assanasen RM Naclerio 2002 Antiallergic anti-inflammatory effects of H1-antihistamines in humans Clin Allergy Immunol 17 101 139 12113215 1:CAS:528:DC%2BD38XmsFajt7c%3D
22. Y Minai-Fleminger F Levi-Schaffer 2009 Mast cells and eosinophils: the two key effector cells in allergic inflammation Inflamm Res 58 10 631 638 19440657 10.1007/s00011-009-0042-6 1:CAS:528:DC%2BD1MXhtFaqsLrJ
23. CH Lin YL Lai 2005 Mast cell mediators in citric acid-induced airway constriction of guinea pigs Toxicol Appl Pharmacol 206 3 343 350 16039945 10.1016/j.taap.2004.11.023 1:CAS:528:DC%2BD2MXmsVWgurg%3D (Pubitemid 41020676)
24. B Bresnihan, et al. 1998 Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist Arthritis Rheum 41 12 2196 2204 9870876 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2 1:CAS:528:DyaK1MXksl2nsw%3D%3D (Pubitemid 29009378)
25. G Nuki, et al. 2002 Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial Arthritis Rheum 46 11 2838 2846 12428223 10.1002/art.10578 1:CAS:528:DC%2BD38XptlSlu7Y%3D (Pubitemid 35315874)
26. Fleischmann RM (2003) Addressing the safety of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford) 42(Suppl 2):ii29-35 (Pubitemid 37220898)
27. SB Cohen, et al. 2004 A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate Ann Rheum Dis 63 9 1062 1068 15082469 10.1136/ard.2003.016014 1:CAS:528:DC%2BD2cXnvFWktrg%3D (Pubitemid 39120355)
28. RM Fleischmann, et al. 2006 Safety of extended treatment with anakinra in patients with rheumatoid arthritis Ann Rheum Dis 65 8 1006 1012 16396977 10.1136/ard.2005.048371 1:CAS:528:DC%2BD28XosFahurw%3D (Pubitemid 44133261)
29. X Le Loet, et al. 2008 Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA trial J Rheumatol 35 8 1538 1544 18634163